Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
immunoPET Imaging Probes for Digestive System Carcinoma
NCT06715839Recruiting
- Sponsor
- Renji Hospital
- Start
- Dec 2024
- Primary completion
- Sep 2027
- Modality
- Recombinant Proteins and Enzymes, Nanobodies (VHH), Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of [68Ga]Ga-DOTA-H2D3, [18F]F-RESCA-RB14, [68Ga]Ga-NOTA-T4, [18F]AlF-RESCA-T4, [68Ga]Ga-NOTA-G5 and 5 more in gastrointestinal carcinoma, sponsored by Renji Hospital. Primary endpoints: Biodistribution at 1 day, Standardized uptake value at 1 day and 3 more. Started Dec 2024; status: recruiting.
02
Drugs
[68Ga]Ga-DOTA-H2D3[18F]F-RESCA-RB14[68Ga]Ga-NOTA-T4[18F]AlF-RESCA-T4[68Ga]Ga-NOTA-G5
03
Conditions
gastrointestinal carcinoma
Beyond the preview
Go deeper on NCT06715839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06715839.